Purple Biotech Reports CAPTN-3 Antibodies Show Strong Anti-Tumor Activity in Preclinical Studies
I'm PortAI, I can summarize articles.
Purple Biotech Ltd. announced positive preclinical results from its CAPTN-3 tri-specific antibody platform, presented at the ESMO Immuno-Oncology Congress 2025. The antibodies IM1240 and IM1305 showed strong anti-tumor activity, with IM1240 contributing to immune activity in PD1-resistant tumors and IM1305 causing tumor regression in breast cancer models. This highlights the platform's potential in overcoming immune failure in solid tumors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments